Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial.

Nature medicine - 1 Mar 2023

Rosenson Robert S, Gaudet Daniel, Ballantyne Christie M, Baum Seth J, Bergeron Jean, Kershaw Erin E, Moriarty Patrick M, Rubba Paolo, Whitcomb David C, Banerjee Poulabi, Gewitz Andrew, Gonzaga-Jauregui Claudia, McGinniss Jennifer, Ponda Manish P, Pordy Robert, Zhao Jian, Rader Daniel J

Abstract excerpt

Severe hypertriglyceridemia (sHTG) is an established risk factor for acute pancreatitis. Current therapeutic approaches for sHTG are often insufficient to reduce triglycerides and prevent acute pancreatitis. This phase 2 trial ( NCT03452228 ) evaluated evinacumab (angiopoietin-like 3 inhibitor) in three cohorts of patients with sHTG: cohort 1, familial chylomicronemia syndrome with bi-allelic loss-of-function...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Disease
Share to Hyperlipoproteinemia Type I

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hypertriglyceridemia

Share to Lipoprotein Lipase

Share to Mutation

Share to Pancreatitis

Share to Single-Blind Method

Share to Triglycerides

Source

Open in PubMed Open full text

Identifiers

PMID: 36879129
DOI: 10.1038/s41591-023-02222-w
PMCID: PMC10033404

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial.PMID 36879129Read ↗

Clinical identification of familial chylomicronemia syndrome and novel therapeutic options.Semantic proximity Read ↗

Hypertriglyceridemia-Causes, Significance, and Approaches to Therapy.Semantic proximity Read ↗

Novel Therapeutics for Familial Chylomicronemia SyndromeSemantic proximity Read ↗

Severe hypertriglyceridemia: Existing and emerging therapiesSemantic proximity Read ↗

Selective Targeting of Angiopoietin-like 3 (ANGPTL3) with Vupanorsen for the Treatment of Patients with Familial Partial Lipodystrophy (FPLD): Results of a Proof-of-Concept StudySemantic proximity Read ↗

Monogenic hypertriglyceridemia and recurrent pancreatitis in a homozygous carrier of a rare APOA5 mutation: a case report.Semantic proximity Read ↗

Hypertriglyceridemic acute pancreatitis in emergency department: Typical clinical features and genetic variants.Semantic proximity Read ↗

Genetic Determinants of Severe Hypertriglyceridemia: Rare Variants in LPL, APOC2, APOA5, GPIHBP1, LMF1, APOE and Polygenic Risk.Semantic proximity Read ↗

Genetic and biochemical analysis of severe hypertriglyceridemia complicated with acute pancreatitis or with low post-heparin lipoprotein lipase mass.Semantic proximity Read ↗

Genetic Variants Associated with Severe Hypertriglyceridemia: LPL, APOC2, APOA5, GPIHBP1, LMF1, and APOE.Semantic proximity Read ↗

Contemporary Management of Familial and Multifactorial Chylomicronemia Syndromes in Italy: Insights From the National LIPIGEN Registry.Semantic proximity Read ↗

Hypertriglyceridemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.